HOUSTON (PRWEB)
May 19, 2020

Mesothelioma Lawyers offer the best service that the world of asbestos has ever seen. The site provides advice and connects people with the best possible mesothelioma lawyer for any individual circumstances. No matter what the diagnosis, Mesothelioma Lawyers are the best people to help anyone to find the most appropriate lawyer for the specific conditions.

The site offers highly relevant information based on different aspects of lung damage caused by asbestos. Therefore, helping the process of choosing the right lawyer in the right area.

Mesothelioma claims can be complicated and confusing. Finding a qualified mesothelioma lawyer is an essential step for any family. The dedication to people affected by mesothelioma is second to none. Treating any asbestos disease is expensive, but Mesothelioma Lawyers believe the victim should not have to foot that bill.

Here are some of the aspects that the site will provide information about:

• Pleural Mesothelioma – A rare but aggressive cancer that envelopes the lungs and chest wall. Affecting ~3,000 people per year, you need a specialist lawyer to get you the right compensation.
• Peritoneal Mesothelioma – Another aggressive and rare cancer, but of the peritoneum. This mesothelioma accounts for 7-20% of all malignant cases.
• Pericardial Mesothelioma – Extremely rare, affecting the lungs, abdominal cavity and heart.
• Mesothelioma and Asbestos Trust Funds – These trust funds are to compensate people diagnosed with asbestos-related diseases. The site also contains a list of the inactive trust funds
• Mesothelioma Symptoms – As symptoms often occur many years after exposure, it is vital to understand and recognize the signs as early as possible.
• Asbestos Legal – This section allows the calculation of compensation, find lawyers, law firms, and other vital, legal information.
• Veterans and Mesothelioma – There is also a dedicated section for armed forces veterans.

The truth of it is that, unfortunately, people have been exposed to asbestos for a long time. That fact raises another disturbing fact; people will get asbestos-related diseases. The only thing that anyone can do is to prepare and be there for the people who need help.

The mission is simple: Connect people diagnosed with mesothelioma with a leading lawyer to pursue the highest compensation possible. Furthermore, to give people the most relevant information that there is for anyone that is affected by all and any asbestos-related diseases.

Mesothelioma Lawyers have worked with thousands of people. Furthermore, they have helped in some of the largest settlements in the world. The largest recorded settlement is an enormous $250 Million, and negligent companies have already set aside over $30 Billion ready to pay the compensation that far too many people deserve.

For any further information, make sure that you visit mesitheliomalawyers.com today.

MEDIA CONTACT:

WEBSITE: https://mesotheliomalawyers.com/

PHONE NUMBER: 1-800-966-2244

EMAIL: info@mesotheliomalawyers.com

Share article on social media or email:

Dr. Kent Sasse

RENO, Nev. (PRWEB)
May 19, 2020

Today Dr. Kent Sasse announced the issuance of a non-provisional patent for his new sleeve tube device, a major breakthrough in the field of metabolic surgery. Millions with type 2 diabetes will benefit from Dr. Sasse’s revolutionary device – the best cure for diabetes.

The new device, Non-Provisional Patent Serial No. 15/838,057, H & H Reference No. (88537.0006), is designed to improve the sleeve gastrectomy procedure, a metabolic surgery that reduces the risk of life-threatening weight-related health conditions, including type 2 diabetes.

Unlike previous devices, the sleeve tube takes its shape from the natural contours of the body and curvature of the stomach, enabling the surgeon to perform each procedure in a manner that conforms to the human body and produces a more natural result.

“The sleeve tube is the culmination of years of work to make sleeve gastrectomy safer, simpler and more effective,” says inventor Dr. Sasse. Dr. Sasse is the medical director of a nationally accredited center for metabolic and bariatric surgery that has produced a breakthrough in reducing the leak rate to 0.0% in over 2,500 consecutive sleeve gastrectomy procedures.

“Through years of study of sleeve gastrectomy, we determined where the increased pressure zones arise, and how to lower complications of leak and stenosis with this new device,” says Dr. Sasse. With continuing innovations like the Sleeve Tube, Dr. Sasse says, “Metabolic surgery today is a 45-minute procedure with four Band-aids that is safer than an appendectomy. More importantly, it is the safest and most effective treatment of type 2 diabetes today.”

About Sleeve Gastrectomy

Also known as laparoscopic sleeve gastrectomy (LSG), sleeve gastrectomy is one of the most performed and successful minimally invasive surgical procedures available today. In addition to being the safest and most effective treatment for type 2 diabetes and obesity, sleeve gastrectomy reduces the risk of heart disease, stroke, infertility, degenerative joints and obstructive sleep apnea.

Learn more about sleeve gastrectomy.

About Dr. Sasse

Kent C. Sasse MD, MPH, FACS, FASCRS, FASMBS, is an honors graduate of the University of California, San Francisco, and holds multiple board certifications including with the American Society for Metabolic and Bariatric Surgery. Dr. Sasse has received numerous honors over the course of his distinguished career and has a deep-rooted passion for teaching, innovation and metabolic health. He is a member of the faculty of the University of Nevada School of Medicine and the author of The Type II Diabetes Cure, a 2019 book on metabolic surgery and diabetes. Learn more about Dr. Sasse at http://www.sassesurgical.com.

For Media Inquiries, please contact Dr. Sasse:

(775) 829-7999

info@sassesurgical.com

Share article on social media or email:

www.4medica.com

“HIEs working at their fullest potential are powerful forces enhancing state efforts to improve care, especially now during the COVID-19 pandemic crisis,” said Gregg Church, President of 4medica.

MARINA DEL REY, Calif. (PRWEB)
May 19, 2020

Idaho Health Data Exchange (IHDE) is on the fast track to improve its ability to match patients records that come from different healthcare delivery settings. Identity management is at the heart of sharing health information and is essential to building the most comprehensive and accurate health record. Today, the IHDE announced its partnership with 4medica® to implement and operate a powerful end-to-end cloud-based enterprise master patient index (eMPI) solution and sophisticated master data clean-up service to improve the health and lives of its patients statewide.

IHDE is augmenting its current eMPI software to increase the accuracy of patient matches with the proven combination of 4medica Big Data MPI™ and 4medica 1% as-a-Service™, a real-time, transactional cloud-based service that leverages innovative technologies, people and proven processes. The hybrid approach affordably, precisely and quickly assesses, normalizes and cleanses patient identity data to guarantee a 99 percent clean database, which is considered foundational for patient safety, data integrity and interoperability.

“As we onboard new technologies and processes to support new growth strategies, we’re bringing 4medica aboard to provide the most accurate patient matching and identity information in the fastest and easiest way possible to our participants,” said Hans Kastensmith, Executive Director of IHDE. “We want our data quality to be transparent, sustainable, reliable and solid to help our provider community deliver the best quality care coordination and population health management in real time.”

“HIEs working at their fullest potential are powerful forces enhancing state efforts to improve care, especially now during the COVID-19 pandemic crisis,” said Gregg Church, President of 4medica. “No single MP technology or referential matching service can solve every patient matching problem. With 4medica, medical professionals in Idaho can be confident of having the most up-to-date exact records at the right time to treat the right patients.”

Kastensmith noted that IHDE is contributing to holistic care by establishing new health data sources, such as those from various state departments, as well as incorporating behavioral health data. The ultimate goal is to give Idaho providers a well-rounded longitudinal medical record.

“Idaho is considered a rural state and hence we provide data exchange services to many critical access hospitals and rural community clinics,” Kastensmith said. “We are excited to partner with 4medica to lower our duplication issues immediately and deliver a complete picture of a patient’s medical history for better care and pandemic response purposes ─ regardless of the provider’s location.”

“Whether the patient has a ski accident and is taken to a hospital ER or is diagnosed with the coronavirus, we want every clinician who treats that individual to have the most relevant encounter data to make the most informed treatment decision,” he added.

About Idaho Health Data Exchange

The Idaho Health Data Exchange (IHDE) is a non-profit 501(c)(3) company. IHDE was created in 2008 as a result of the efforts of the Health Quality Planning Commission. The Commission was charged with promoting improved quality of care and health outcomes through investment in health information technology. IHDE is a Health Information Exchange (HIE) that enables doctors, nurses, labs, and other medical providers to securely access their patient’s electronic health information quickly, 24/7/365, to improve the speed, quality, safety, and cost of patient care. For more information, visit: https://www.idahohde.org/

About 4medica

Guaranteeing an unprecedented 1% patient record duplication rate, 4medica® solves data integrity and financial challenges to minimize patient safety and other clinical risks and achieve true clinical interoperability and transparency for patients. Our Big Data Management and Clinical Data Exchange cloud solutions help healthcare organizations facilitate patient identity management and data exchange to ensure the right data is captured at the right time, the first time. 4medica’s Perfect Order for Perfect Payment™ ensures labs and imaging centers get paid by integrating high-volume revenue cycle management services throughout the entire order management process. 4medica has processed up to 6 billion clinical results representing more than 70 million patient identities. The company connects 40,000-plus physicians to hundreds of ACOs, HIEs, HINs, hospitals, health systems, laboratories, radiology imaging centers and payers nationwide. Learn more at http://www.4medica.com.

Share article on social media or email:

Psychotherapist Jenn Tomko LCSW

Psychotherapist Jennifer Tomko, LCSW notices similar struggles between COVID-19 and those with post 9/11 trauma. The trend she says is adding to higher anxiety levels with survivors of both 9/11 and the COVID pandemic.

JUPITER, Fla. (PRWEB)
May 19, 2020

The pandemic is bringing up many frightening feelings in people, but those experiencing some of the worst anxiety are 9/11 survivors. The issues COVID-19 brings up are similar to the trauma people experienced due to Sept. 11, South Florida psychotherapist Jennifer Tomko, LCSW says.

Tomko says while a terrorist attack and a pandemic are very different, the sense of powerlessness is the same. “There are many factors that are out of everyone’s control,” says Tomko. “Witnessing patients suffer with sickness and losing their battle with Coronavirus is negatively impacting the mental state of frontline workers, as was made evident by the reported suicide of an ER doctor in New York.” Many people enter the medical and emergency response fields because it is in their nature to help, cure, and fix. Tomko says when they are unable to do so, they can experience depression, anxiety, and PTSD, to name just a few common mental health issues.

Additionally, from inhaling all of the toxic air and fumes in Manhattan, many 9/11 survivors suffer from respiratory conditions and lung disease. This puts them at a higher risk for COVID-19 being fatal if contracted, further adding to their anxiety levels.

Tomko is certified by the World Trade Center Health program Elite E-Counseling, LLC. She and a 9/11 survivor are available for broadcast, print, and digital interviews to discuss the similarities between both traumatic events. Tomko has appeared on WPTV and WPEC in West Palm Beach and has been interviewed by Woman’s Day, Thrive Global, and Medium.

Share article on social media or email:

Kenneth Walz Joins Eaton Square

“At Popper and Company, we are excited to be bringing our deep industry expertise to Eaton Square and we look forward to helping grow the firm’s presence in life sciences and med-tech in the U.S. and globally,” Ken Walz, Partner and Principal

BALTIMORE (PRWEB)
May 19, 2020

Eaton Square is pleased to announce its growth on the East Coast of the US with the addition of Popper and Company, a biotechnology and medical technology-focused strategy and M&A advisory firm.

This is an important step for Eaton Square as it continues to grow in the United States, linking US and Asia Pacific healthcare innovators with capital and investors.

Popper and Company, founded in 2003 by Caroline Popper, MD and Ken Walz, helps clients in clinical diagnostics, medical devices, life science tools, and digital health, providing guidance on a variety of commercialization challenges.

The biotechnology and life sciences sector is key to Eaton Square’s continued growth as a cross-border M&A and capital services firm. Given the current global environment, biotechnology is predicted to continue to be extremely active in M&A activity driven by initiatives from large global and regional pharmaceutical companies.

“Eaton Square is focused on assisting clients to grow across the US and internationally. We believe the combination of Popper and Company with our existing Life Sciences and Healthcare capabilities significantly enhances our ability to assist clients in the US and Asia Pacific to undertake transactions and attract capital globally.” Nick Weston, Managing Principal, Eaton Square.

“We are looking forward to initiating global and regional cross-border solutions for pharma, biotech and med-tech sectors. These now include M&A, debt and equity solutions, strategy and advisory. This will give Eaton Square a strong biotech, healthcare, device and A.I. presence in the US and Asia Pacific,” Bob Atwill, Eaton Square Principal.

“At Popper and Company, we are excited to be bringing our deep industry expertise to Eaton Square and we look forward to helping grow the firm’s presence in life sciences and med-tech in the U.S. and globally,” Ken Walz, Eaton Square Principal.

“I am excited to welcome the Popper and Company team to enable us to service more clients looking to grow in the healthcare space. Their presence in the Baltimore/DC area will also strengthen our presence in the East Coast of the United States,” Reece Adnams, Eaton Square CEO.

Joining the Eaton Square Biotech team are:

Ken Walz

Principal

Ken Walz has worked for more than 25 years in the biotech, diagnostics, and medical device industries in business development and finance roles and is particularly interested in the application of disruptive technologies to address inefficiencies in the healthcare system. He brings broad experience in commercial operations and strategy development and has extensive experience leading transaction processes. At Popper and Company, he assists clients in all aspects of strategy and corporate development including strategic partnership development, transaction process management, and health economic modeling.

Prior to Popper and Company, Ken held senior positions at MDS Proteomics and Becton Dickinson. Ken holds a BA in Economics from the University of Maryland Baltimore County and an MS in Finance from Loyola College of Maryland.

Caroline Popper, MD

Principal

Caroline is a physician with more than 25 years of hands-on operating experience within health care companies. She has managed a wide spectrum of diagnostics, device and drug discovery businesses in both Fortune 500 and start-up settings, at amongst others, Becton Dickinson, bioMerieux, and MDS. She co-founded Popper and Company with Ken Walz specifically to bring integrated strategic and operational expertise to healthcare clients. She earned her medical degree at the University of the Witwatersrand, South Africa and completed post-graduate training in internal medicine and pathologist at Johns Hopkins in Baltimore. She also trained in Health Policy and Health Economics at the Johns Hopkins Bloomberg School of Public Health.

Eaton Square, a cross-border M&A and capital services firm, now has a total of 19 offices across the US, Canada, China & Hong Kong, Australia, New Zealand, UK, Switzerland, Singapore and Israel.

If you would like to arrange a time to speak with our Life Sciences and Healthcare team, please contact them at:

Ken Walz – ken.walz@eatonsq.com

Caroline Popper – caroline.popper@eatonsq.com

Bob Atwill – bob.atwill@eatonsq.com

Nick Weston – nicholas.weston@eatonsq.com

Reece Adnams – reece.adnams@eatonsq.com

Share article on social media or email:

Aeroflow Healthcare survey results highlight the prominence of incontinence in middle-age women while also displaying the lack of education and available resources.

“This study confirms what we already suspected: that social stigma and a lack of education about incontinence stand in the way of treatment,” said Aleece Fosnight, PA-C and Medical Advisor for Aeroflow Urology. “Without proper treatment, incontinence can snowball into larger health issues.”

ASHEVILLE, N.C. (PRWEB)
May 19, 2020

Aeroflow Healthcare, a nationwide provider of durable medical equipment, announced today the results of a proprietary survey designed to highlight the struggle and stigma middle-aged women experience with incontinence. The third-party administered survey polled 1010 adult women aged 40 to 64 living in the United States and was completed on March 16, 2020. The full survey results can be found here.

The survey’s key findings fall within three main categories:

Prevalence:

• Incontinence is very common among women aged 40-64, with almost 3/4 (72%) of women surveyed having experienced issues with bladder control or leakage, and 74% first experiencing incontinence between those same ages.
• 65% say they experience bladder leakage at least once a month and for 1 in 4 women, it is a daily occurrence.

Stigma:

• 52% of middle-aged women have tried to hide loss of bladder control after experiencing it in public, while another 42% are embarrassed to discuss it with family or friends, indicating a strong incontinence stigma.
• For over half of these women (53%), incontinence affects their daily lives and activities, including work, career, education, ability to exercise, ability to run errands, and even their ability to attend social gatherings.

Lack of Education and Treatment:

• More than half of women surveyed (56%), did not visit a healthcare provider after experiencing loss of bladder control, and 37% said they did not seek treatment because they did not think it was a big deal, illustrating a lack of education and awareness around incontinence.

The results of this survey highlight how far society still has to go in promoting awareness and discussing incontinence, and shows that women are led to believe bladder control and leakage are merely a normal process of aging.

“This study confirms what we already suspected: that social stigma and a lack of education about incontinence stand in the way of treatment,” said Aleece Fosnight, PA-C and Medical Advisor for Aeroflow Urology. “Breaking down those barriers is such an important step in preventative treatment and normalizing incontinence. Without proper treatment, incontinence can snowball into larger health issues such as urinary tract infections, kidney failure, and depression, and can even impact life issues like personal finance.

“Incontinence shouldn’t be embarrassing, but it all starts with healthcare providers educating patients on the symptoms, how common this issue is and how to address it. We hope this study raises awareness around the prevalence of incontinence in all women and how important it is for us to start having meaningful conversations on the topic to ultimately drive earlier detection and treatment for patients.”

About Aeroflow Healthcare

Aeroflow Healthcare was founded in Asheville, NC in 2001 as a home oxygen provider, and has since grown to become a nationwide provider of durable medical equipment. In 2017, Aeroflow was also awarded the HME Excellence Award for Best Home Medical Equipment Provider and has been recognized as a business offering top-notch benefits to employees with the Great Place to Work Award. Aeroflow is an accredited Medicare and Medicaid provider and accepts most commercial insurance. To learn more about Aeroflow Healthcare and getting medical equipment through insurance, visit aeroflowinc.com.

Media Inquiries

Kyle Evans

FischTank PR

Email: kyle@fischtankpr.com

Aeroflow Contact

Kristin Robinson

Marketing Manager, Aeroflow Urology

Email: kristin.robinson@aeroflowinc.com

Share article on social media or email:

ERT’s Virtual Visit solution keeps clinical trial patients and investigative sites connected and better engaged during/after COVID-19.

“We’re pleased to offer another significant capability in a series of revolutionary virtual trial solutions to support our customers as they address the challenges presented by COVID-19,” said Matthew McCarty, Vice President, Digital Patient at ERT.

PHILADELPHIA (PRWEB)
May 19, 2020

ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a Virtual Visit solution that enables the continuation of clinical trials during and after current global stay-at-home mandates.

As a result of COVID-19, many clinical trials have been delayed as healthcare providers focus their efforts on patients who require urgent care, which limits clinical trial patients’ access to investigative sites for routine visits. In order to keep their studies on track, clinical trial sponsors and CROs need innovative solutions that enable investigative site personnel and patients to interact with each other, regardless of their physical location (often referred to as TeleHealth).

ERT’s Virtual Visit solution enables at-home consultations between patients and investigative site personnel via a seamless, dedicated, secure app or web interface. The offering allows patients to consult with their clinicians safely from home, simplifying their participation in clinical trials and enabling researchers to continue collecting the important safety and efficacy data needed to support their development objectives. The solution complements ERT’s suite of safety and efficacy data capture solutions, improving patient engagement throughout ongoing and new clinical trials.

“We’re pleased to offer another significant capability in a series of revolutionary virtual trial solutions to support our customers as they address the challenges presented by COVID-19,” said Matthew McCarty, Vice President, Digital Patient at ERT. “Our research indicates that nearly 80% of the industry is shifting to virtual trial solutions during this unprecedented time and we remain committed to delivering the dynamic tools they need to continue their important, life-saving research.”

Click here to learn more about ERT’s Virtual Visit solution.

About ERT

ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

For more information, go to ert.com or follow us on LinkedIn and Twitter.

Share article on social media or email: